Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPLAGAL in Treatment-naïve Chinese Subjects With Fabry Disease
NCT04974749Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2022
- Primary completion
- Jan 2024
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of agalsidase alfa in Fabry disease (FD), sponsored by Takeda. Primary endpoint: Number of Participants With Serious Treatment-emergent Adverse Events. Started May 2022; status: completed.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT04974749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04974749.